middle.news
Nexalis Therapeutics Halts Point8 Funding Talks, Completes IRX-616a Phase 1 Trial with Positive Results
11:48am on Monday 6th of July, 2026 AEST
•
Healthcare
Read Story
Nexalis Therapeutics Halts Point8 Funding Talks, Completes IRX-616a Phase 1 Trial with Positive Results
11:48am on Monday 6th of July, 2026 AEST
Key Points
Point8 Capital funding negotiations ceased
IRX-616a Phase 1 trial confirms safety and tolerability
LFO funding facility cancelled with outstanding drawdowns
Clinical trials temporarily suspended pending funding
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexalis Therapeutics (ASX:NX1)
OPEN ARTICLE